Myers Michael's Form 4 filing
Quoin Pharmaceuticals Ltd. (QNRX) · filed Sep 5, 2024
- Accession no.
- 0001104659-24-097254
- Filed
- Sep 5, 2024
- Trade date
- Sep 3-4, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $29.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Myers MichaelCIK 0001959547 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2024 | Ordinary Shares | PPurchaseAcquired | +800 | $0.62 | +$496 | 10,158 | Direct | |
| Sep 4, 2024 | Ordinary Shares | PPurchaseAcquired | +5,322 | $0.66 | +$3,512.52 | 15,480 | Direct | |
| Sep 4, 2024 | Ordinary Shares | PPurchaseAcquired | +8,200 | $0.75 | +$6,150 | 23,680 | Direct | |
| Sep 4, 2024 | Ordinary Shares | PPurchaseAcquired | +23,572 | $0.80 | +$18,857.6 | 47,252 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.